SecBot SecBot
SC 13G/A ·Filed Nov 16, 2026

YARW

Yarrow Bioscience, Inc.
NEUTRAL
Impact 3/10
Horizonweeks Processed1d 6h ago SEC0002147397-26-000003
Passive stake amendment
Actionable Insight • Neutral

Monitor for any conversion of this 13G to a 13D (activist filing) or further stake increases. The cluster of institutional filings post-offering suggests a stable shareholder base, but the 9.9% position is near the threshold that could trigger activist considerations.

DirectionNeutral
Confidencehigh
Horizonweeks

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

RTW Fund Group GP, LLC filed an amended Schedule 13G disclosing a 9.9% beneficial ownership stake in Yarrow Bioscience as of September 30, 2026, representing 1,145,149 shares (including warrants). This is an increase from a prior filing (0.46% by Nantahala Capital) and adds to a series of recent 13G filings by other institutions (Bellevue Group at 10.6%, Spruce Street at 6.4%) following Yarrow's September 2026 equity offering. The passive certification and hedge fund identity suggest a routine investment, not an activist precursor.

Key Financial Metrics

Stake
9.9%
Stake Value
$18.1M
Investor
RTW Fund Group GP, LLC
Investor Type
hedge fund

Key Facts

  • RTW Fund Group GP, LLC disclosed a 9.9% beneficial ownership stake in Yarrow Bioscience as of September 30, 2026.
  • The stake includes 1,145,149 shares of common stock, with warrants exercisable up to a 9.99% ownership cap.
  • This is an amendment to a prior Schedule 13G filed on July 30, 2026, reflecting an increased position.
  • The filing is passive (Rule 13d-1(b)) with no activist intent certified.
  • Other recent 13G filers include Bellevue Group (10.6%) and Spruce Street Capital (6.4%).

Financial Impact

9.9% stake valued at approximately $18.1M based on $183M market cap.

ownership concentration

Risk Factors

  • Potential future conversion to activist filing (13D) if intent changes.
  • Dilution risk from outstanding warrants and recent equity offering.
  • Pre-revenue clinical-stage biotech with no approved products.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (9 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
SC 13G/A Filing (Primary)0002147397-26-000003
Document: 0002147397-26-000003-index.html0002147397-26-000003
Document: 0002147397-26-000003.txt0002147397-26-000003

Track record

13 reports on YARW

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 17, 2026today SC 13G/A Neutral 3/10 Entry $13.93 Now $14.27 +2.44% settles Dec 16
  2. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $14.20 Now $14.27 +0.49% settles Dec 16
  3. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $13.93 Now $14.27 +2.44% settles Dec 16
  4. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $13.93 Now $14.27 +2.44% settles Dec 16
  5. Nov 16, 20261d ago SC 13G/A Neutral 3/10 Entry $15.44 Now $14.27 −7.58% settles Dec 15
  6. Nov 16, 20261d ago SC 13G Neutral 3/10 Entry $18.20 Now $14.27 −21.59% settles Dec 15
  7. Nov 16, 20261d ago SC 13G/A Neutral 3/10 Viewing Entry $18.03 Now $14.27 −20.85% settles Dec 15
  8. Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $17.35 Now $14.27 −17.75% settles Dec 15
  9. Nov 13, 20263d ago SC 13G Neutral 3/10 Entry $18.03 Now $14.27 −20.85% settles Dec 15
  10. Nov 12, 20265d ago 8-K Neutral 4/10 Entry $19.63 Now $14.27 −27.31% settles Dec 11
Showing 10 of 13

US Market Status

Market Open · Closes in 22m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 16, 2026